Duration of fracture prevention after zoledronate treatment in women with osteopenia: observational follow-up of a 6-year randomised controlled trial to 10 years
The reduced fracture rates following zoledronate in the core trial were substantially maintained for 1·5–3·5 years after the last zoledronate infusion, but not thereafter.